Omapix
OMAPiX is a privately held spatial omics services company delivering end-to-end spatial transcriptomics, proteomics, and single-cell multiomics solutions through multiple best-in-class technology platforms to pharmaceutical, biotech, and academic research customers across the US and Europe.
- Company typePrivate
- Founded2021
- HeadquartersLeuven, Belgium
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Omapix does
OMAPiX is a privately held spatial omics services company founded in 2021 and headquartered in Leuven, Belgium, with operating subsidiaries in Frederick, Maryland (USA) and Langenfeld, Germany. The company was originally established as the European Spatial Biology Center and rebranded to OMAPiX in June 2023. It operates with 1–10 disclosed employees as an end-to-end contract research organization delivering spatial biology services to pharmaceutical/biotech organizations and academic research institutions across applications including cancer biology, biomarker discovery, immunology, neurology, cell and gene therapy, and rare diseases.
The core offering is platform-agnostic access to spatial omics technologies under a 'concierge' model: single-cell sequencing on 10x Chromium X, BD Rhapsody, Parse Biosciences and BioSkryb; spatial transcriptomics on 10x Visium CytAssist, Curio Seeker and Curio Trekker; in situ sequencing on 10x Xenium and Vizgen MERSCOPE; high-throughput sequencing on Element AVITI/AVITI24; and subcellular spatial proteomics via the Syncell Microscoop partnership. Custom bioinformatics services cover QC, expression normalization, segmentation, cell typing, cell-cell distances, cell-cell communication, niche analysis, and protein network analysis, with compute delivered through an Oracle Cloud Infrastructure collaboration that supplies GPU-accelerated analysis and a quarriable multimodal data layer for pharma customers.
OMAPiX generates revenue through professional services fees on a quote basis, tailored to each project's scope, technology mix, and analysis depth. The go-to-market is consultative enterprise field sales supported by content marketing via its website and direct engagement through LinkedIn and Twitter. The firm monetizes its position as a Certified Service Provider for Parse Biosciences and BioSkryb Genomics, and as a strategic partner for Vizgen, Resolve Biosciences, Ultivue, and Syncell, channeling end-user demand into its laboratories.
Omapix firmographics
Firmographics- Name
- Omapix
- Legal name
- OMAPiX GmbH
- Website
- https://omapix.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- OMAPiX is a privately held spatial omics services company delivering end-to-end spatial transcriptomics, proteomics, and single-cell multiomics solutions through multiple best-in-class technology platforms to pharmaceutical, biotech, and academic research customers across the US and Europe.
- Ownership category
- akta.pro rank
Omapix industry classification
Industry- Product category
- Contract Research Services
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Single-Cell & Spatial Omics Services (HLAGANAC)
- akta.pro secondary industries
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where Omapix is headquartered
LocationHeadquarters
- HQ city
- Leuven
- HQ country
- Belgium
- HQ region
- Europe
Offices3 records
Markets served
Omapix business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Spatial Omics Services: OMAPiX generates revenue through providing comprehensive end-to-end spatial omics services including single cell sequencing, spatial transcriptomics, in situ sequencing, high throughput sequencing, and bioinformatics data analysis solutions. Services are tailored from scientific consultancy to data analysis, supporting projects across therapeutic areas and indications.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Omapix product offering
Product offeringCore offering
Omapix is an end-to-end spatial omics services company that provides customized spatial biology solutions for pharmaceutical, biotech, and academic research customers. The company delivers services spanning scientific consultation, target/panel selection, sample processing, and custom bioinformatics data analysis, leveraging multiple complementary third-party spatial omics platforms (10x Genomics, Vizgen MERSCOPE, Curio, Parse Biosciences, BioSkryb, Element AVITI, Ultivue, Resolve Biosciences).
Product overview
OMAPiX is an end-to-end spatial omics services company offering a portfolio of technology platforms for single-cell sequencing, spatial transcriptomics, in situ sequencing, and high-throughput sequencing. The core offering includes 10x Genomics Chromium X, BD Rhapsody, BioSkryb, and Parse Biosciences for single-cell applications; 10x Visium CytAssist and Curio Seeker/Trekker for spatial transcriptomics; 10x Genomics Xenium and Vizgen MERSCOPE for in situ sequencing; and Element AVITI/AVITI24 for sequencing. Services are delivered through a concierge approach combining scientific consultation, target/panel selection, sample processing, and comprehensive bioinformatics and data analysis solutions. The company operates as a CRO providing customized spatial biology solutions for pharma, biotech, and academic research across applications including cancer biology, biomarker discovery, neurology, immunology, cell and gene therapy, and rare diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- Single Cell Sequencing Services End-to-end single-cell sequencing services for pharma, biotech, and academic researchers using multiple complementary platforms (10x Genomics Chromium X, BD Rhapsody, BioSkryb, Parse Biosciences) supporting 3', 5' and immune profiling, ATAC, multiome, fixed, and nuclei applications with up to 1 million cells per single assay.
- Spatial Transcriptomics Services Spatial transcriptomics services using 10x Visium CytAssist, Curio Seeker, and Curio Trekker platforms, providing unbiased whole-transcriptome analysis with sub-cellular resolution across fresh frozen and FFPE tissue samples for discovery and translational research applications.
- In Situ Sequencing Services In situ sequencing services using 10x Genomics Xenium (up to 5,000 plex RNA detection) and Vizgen MERSCOPE (up to 1,000 plex RNA detection with protein co-detection) platforms, with FFPE and fresh frozen compatibility and optional post-processing protein detection (Akoya, IF, H&E).
- High Throughput Sequencing Services High-throughput sequencing services using Element AVITI and AVITI24 platforms, featuring rolling cycle amplification for industry-leading quality scores, up to 2x300bp read lengths, full Illumina library compatibility without conversion reactions, and on-flow cell cytoprofiling (AVITI24).
- Bioinformatics & Data Analysis Solutions Comprehensive bioinformatics support providing in-depth custom data analysis and integrated multimodal analysis including QC evaluations, expression normalization, segmentation, clustering/cell typing, cell-cell distances, cell-cell communication, niche analysis, and protein network analysis for spatial and single-cell datasets.
- Spatial Biology Services End-to-end spatial omics service offering spanning scientific consultation, target/panel selection, sample processing, and standardized analysis, supporting spatial transcriptomics and proteomics with 100+ target RNAs per experiment at sub-cellular resolution, tissue heterogeneity mapping, and cell-typing for projects at any scale from discovery through clinical applications.
Quantifiable outcome
- 100+ target RNAs detected in a single experiment with sub-cellular resolution
- +3 more outcomes
Companies that use Omapix
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Omapix technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Omapix partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered major and core.
- SyncellmajorOMAPiX is Syncell's first preferred service provider for their Microscoop technology - a first-of-its-kind solution for unbiased subcellular spatial proteomics. Through this collaboration, customers can get seamless, end-to-end Syncell Microscoop studies from cells or tissue samples.
- MS BioworksmajorMS Bioworks is Syncell's first preferred partner for mass spec and collaborates with OMAPiX in Syncell's preferred partner network to provide advanced mass spec service and analysis combined with Syncell's Microscoop spatial proteomics technology.
- BioSkryb GenomicscoreOMAPiX welcomed as a Certified Service Provider (CSP) in BioSkryb's CSP Program. BioSkryb Genomics provides single-cell multiomic technology including whole genome single cell analysis using Primary Template-directed Amplification (PTA). This partnership increases researchers' access to single-cell multiomics capabilities.
- Parse BiosciencescoreStrategic partnership making OMAPiX a Certified Service Provider (CSP) offering Parse Biosciences' innovative single-cell sequencing products. Parse Biosciences is a pioneer in scalable single-cell sequencing technology utilizing proprietary fixation and permeabilization method combined with combinatorial barcoding to generate high throughput and high-quality single-cell datasets. This enables researchers to access Parse Biosciences' technology without establishing protocols in their own laboratories.
- Oracle Cloud Infrastructure (OCI)majorOMAPiX moved to Oracle Cloud Infrastructure to leverage powerful infrastructure and scalable GPU-accelerated computing for analyzing vast spatial biology datasets. Utilizing OCI's database technologies including Oracle Application Express (APEX) to build a quarriable registry for pharma customers. This partnership enables multimodal and multilayered data structures from clinical samples for identifying novel spatial signatures predictive of patient response to precision therapies.
- VizgencoreStrategic partnership for MERSCOPE Platform technology. Vizgen's MERSCOPE Platform enables spatial transcriptomics with up to 1,000 plex RNA detection and protein co-detection. OMAPiX scientists use Vizgen technology to provide customers with standardized, reliable, high-quality spatial transcriptomic data.
- Resolve BiosciencescorePartnership for Molecular Cartography technology. Resolve Biosciences enables translational research and drug development communities to apply spatially resolved, high-dimensional, multi-omic analysis at scale, especially for immune response studies.
- UltivuecorePartnership for InSituPlex and UltiStacker technologies. Ultivue enables whole-slide spatial phenotyping for clinical biomarker development with digital pathology offerings, complementing other OMAPiX offerings.
Scale indicators4 records
Recent moves8 records
Expansion highlights5 records
Omapix competitors and assessment
Company assessmentBroad incumbents
- Bio-Techne: Life sciences tools and services company with spatial biology reagents (RNAscope) and adjacent services capabilities. Comparable as a broader spatial biology ecosystem player with overlapping pharma research customers.
- Eurofins Genomics: Large incumbent genomics services business with broad portfolio that has expanded into spatial omics. Comparable as a scaled services provider serving overlapping pharma and academic customers, though broader in scope.
Direct peers
- Vizgen: Developer of the MERSCOPE in situ sequencing platform — a core technology OMAPiX services under a strategic partnership. Direct peer given overlapping spatial transcriptomics services and shared pharma/academic customers.
- Parse Biosciences: Single-cell sequencing platform vendor for which OMAPiX is a Certified Service Provider. Directly comparable in single-cell services, with shared customers and overlapping CSP-driven service delivery model.
- Novogene: Global sequencing and multi-omics services company with spatial transcriptomics offerings. Comparable as a multi-platform omics services provider serving pharma and academic customers across multiple geographies.
- Resolve Biosciences: Molecular Cartography spatial multi-omics platform vendor and OMAPiX strategic partner. Comparable as a high-plex spatial omics service provider targeting translational pharma and academic research customers.
- NanoString Technologies (Bruker Spatial Biology): Spatial biology platform vendor (GeoMx, CosMx) now part of Bruker, with a services arm supporting pharma translational research. Comparable end-to-end spatial omics services offering for similar customer segments.
- 10x Genomics: Provider of Chromium single-cell and Visium/Xenium spatial omics platforms that OMAPiX services on behalf of customers. Directly comparable technology vendor with adjacent service offerings and overlapping customer base in pharma and academic research.
- Curio Bioscience: Spatial transcriptomics platform vendor (Curio Seeker, Curio Trekker) and OMAPiX partner. Directly comparable single-cell and spatial services provider with similar biotech and academic customer base.
- CD Genomics: Genomics and spatial omics services CRO offering single-cell and spatial transcriptomics for pharma and academic customers. Closely comparable as a third-party spatial omics services provider with similar multi-platform positioning.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Omapix social profiles
Digital presenceOmapix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Omapix leadership team
Management profileNumber of profiles
Profiles4 records
Omapix funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Omapix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Omapix
What does Omapix do?
Omapix is an end-to-end spatial omics services company that provides customized spatial biology solutions for pharmaceutical, biotech, and academic research customers. The company delivers services spanning scientific consultation, target/panel selection, sample processing, and custom bioinformatics data analysis, leveraging multiple complementary third-party spatial omics platforms (10x Genomics, Vizgen MERSCOPE, Curio, Parse Biosciences, BioSkryb, Element AVITI, Ultivue, Resolve Biosciences).
Is Omapix a public or private company?
Omapix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Omapix founded?
Omapix was founded in 2021. It employs 1 to 10 people.
Where is Omapix based?
Omapix is headquartered in Leuven, Belgium, in the Europe region.
How does Omapix make money?
One revenue line is on record: spatial Omics Services.
Who are Omapix's main competitors?
Broad incumbents on record are Bio-Techne and Eurofins Genomics. Direct peers are Vizgen, Parse Biosciences, Novogene, Resolve Biosciences, NanoString Technologies (Bruker Spatial Biology), 10x Genomics, Curio Bioscience and CD Genomics.
Does Omapix have an API?
No public API is recorded for Omapix.
What industry is Omapix in?
Omapix's product category is Contract Research Services. Its primary akta.pro industry code is HLAGANAC, Single-Cell & Spatial Omics Services, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its SIC code is 8731.